Inovio Pharmaceuticals, Inc. Share Price & Technical Analysis
INO · $1.31 (-7.09%)
Healthcare / Biotechnology
$1.31
-7.09%
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses SynCon, to help engineer precisely designed plasmid DNA plasmids, as well as CELLECTRA smart devices technology that…
Price chart
Seasonality
May has 2 positive and 3 negative years (last 5 years shown)
27% return in May, -10% avg return in past 3 year May month.
-16% return in 2026, -35% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -11% | 13% | -6% | -39% | 27% | – | – | – | – | – | – | – | -16% |
| 25 | 11% | 0% | -20% | 19% | 5% | 0% | -30% | 71% | 0% | 0% | -9% | -19% | 28% |
| 24 | -10% | 65% | 54% | -19% | -12% | -21% | 32% | -33% | -19% | -7% | -19% | -59% | -48% |
| 23 | 4% | -24% | -36% | -6% | -22% | -25% | 19% | -16% | -11% | -9% | 9% | 30% | -86% |
| 22 | -18% | -23% | 10% | -24% | -32% | -9% | 12% | 16% | -24% | 22% | -5% | -21% | -97% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Downtrend · Uptrend
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses SynCon, to help engineer precisely designed plasmid DNA plasmids, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company's lead product candidate is INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade squamous intraepithelial lesions; INO-3112 for the treatment of HPV-related Oropharyngeal squamous cell carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 2/3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. The company's partners and collaborators ApolloBio Corporation, AstraZeneca, Coherus Biosciences, Defense Advanced Research Projects Agency, HIV Vaccines Trial Network, Kaneka Eurogentec, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter BioLogics, the University of Pennsylvania, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$114.34M
P/E ratio
—
52W high
$2.98
52W low
$1.03
Volume
20,16,862
Beta
1.44
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Inovio Pharmaceuticals, Inc. share price today?
- Inovio Pharmaceuticals, Inc. (INO) last traded around $1.31 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does INO have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for INO. Download the app for real-time alerts.
- How can I analyze Inovio Pharmaceuticals, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.